Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Kirchhof, P; Toennis, T; Goette, A; Camm, AJ; Diener, HC; Becher, N; Bertaglia, E; Blomstrom, Lundqvist, C; Borlich, M; Brandes, A; Cabanelas, N; Calvert, M; Chlouverakis, G; Dan, GA; de, Groot, JR; Dichtl, W; Kravchuk, B; Lubiński, A; Marijon, E; Merkely, B; Mont, L; Ozga, AK; Rajappan, K; Sarkozy, A; Scherr, D; Sznajder, R; Velchev, V; Wichterle, D; Sehner, S; Simantirakis, E; Lip, GYH; Vardas, P; Schotten, U; Zapf, A.
Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes.
N Engl J Med. 2023; 389(13): 1167-1179. Doi: 10.1056/NEJMoa2303062
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Scherr Daniel

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of AHREs in patients without atrial fibrillation (as documented on a conventional electrocardiogram [ECG]) justifies the initiation of anticoagulants is not known. METHODS: We conducted an event-driven, double-blind, double-dummy, randomized trial involving patients 65 years of age or older who had AHREs lasting for at least 6 minutes and who had at least one additional risk factor for stroke. Patients were randomly assigned in a 1:1 ratio to receive edoxaban or placebo. The primary efficacy outcome was a composite of cardiovascular death, stroke, or systemic embolism, evaluated in a time-to-event analysis. The safety outcome was a composite of death from any cause or major bleeding. RESULTS: The analysis population consisted of 2536 patients (1270 in the edoxaban group and 1266 in the placebo group). The mean age was 78 years, 37.4% were women, and the median duration of AHREs was 2.8 hours. The trial was terminated early, at a median follow-up of 21 months, on the basis of safety concerns and the results of an independent, informal assessment of futility for the efficacy of edoxaban; at termination, the planned enrollment had been completed. A primary efficacy outcome event occurred in 83 patients (3.2% per patient-year) in the edoxaban group and in 101 patients (4.0% per patient-year) in the placebo group (hazard ratio, 0.81; 95% confidence interval [CI], 0.60 to 1.08; P = 0.15). The incidence of stroke was approximately 1% per patient-year in both groups. A safety outcome event occurred in 149 patients (5.9% per patient-year) in the edoxaban group and in 114 patients (4.5% per patient-year) in the placebo group (hazard ratio, 1.31; 95% CI, 1.02 to 1.67; P = 0.03). ECG-diagnosed atrial fibrillation developed in 462 of 2536 patients (18.2% total, 8.7% per patient-year). CONCLUSIONS: Among patients with AHREs detected by implantable devices, anticoagulation with edoxaban did not significantly reduce the incidence of a composite of cardiovascular death, stroke, or systemic embolism as compared with placebo, but it led to a higher incidence of a composite of death or major bleeding. The incidence of stroke was low in both groups. (Funded by the German Center for Cardiovascular Research and others; NOAH-AFNET 6 ClinicalTrials.gov number, NCT02618577; ISRCTN number, ISRCTN17309850.).

Find related publications in this database (using NLM MeSH Indexing)

Aged - administration & dosage

Female - administration & dosage

Humans - administration & dosage

Male - administration & dosage

Anticoagulants - adverse effects, therapeutic use

Atrial Fibrillation - complications, diagnosis

Embolism - drug therapy, etiology

Factor Xa Inhibitors - adverse effects, therapeutic use

Hemorrhage - chemically induced

Stroke - etiology, prevention & control

Electrodes, Implanted - administration & dosage

Double-Blind Method - administration & dosage

Arrhythmias, Cardiac - complications, diagnosis

Risk Factors - administration & dosage

© Med Uni Graz • Imprint